271?79. 207. Kosik, K.S.; Shimura, H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim. Biophys. Acta 2005, 1739, 298?10. 208. Avila, J.; Lucas, J.J.; Perez, M.; Hernandez, F. Function of Tau in both physiological and pathological situations. Physiol. Rev. 2004, 84, 361?84. 209. Jeganathan, S.; Hascher, A.; Chinnathambi, S.; Biernat, J.; Mandelkow, E.M.; Mandelkow, E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction in the paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 2008, 283, 32066?2076. 210. Hyman, B.T.; Augustinack, J.C.; Ingelsson, M. Transcriptional and conformational modifications on the tau molecule in Alzheimer’s disease. Biochim. Biophys. Acta 2005, 1739, 150?57. 211. Delacourte, A.; Buee, L. Normal and pathological Tau proteins as variables for microtubule assembly. Int. Rev. Cytol. 1997, 171, 167?24. 212. Johnson, G.V.; Stoothoff, W.H. Tau phosphorylation in neuronal cell function and dysfunction.8-Bromo-3-chloroisoquinoline site J. Cell Sci. 2004, 117, 5721?729. 213. Drechsel, D.N.; Hyman, A.A.; Cobb, M.H.; Kirschner, M.W. Modulation of your dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3, 1141?154. 214. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.; Gertz, H.N.; Xuereb, J.H.; Paykel, E.S.; Brayne, C.; Huppert, F.A.; Mukaetova-Ladinska, E.B.; Mena, R.; et al. Quantitative analysis of tau protein in paired helical filament preparations: Implications for the function of tau protein phosphorylation in PHF assembly in Alzheimer’s disease. Neurobiol. Aging 1995, 16, 409?17.Int. J. Mol. Sci. 2014,215. Feuillette, S.; Miguel, L.; Fr ourg, T.; Campion, D.; Lecourtois, M. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J. Neurochem. 2010, 113, 895?03. 216. Rocher, A.B.; Crimins, J.L.; Amatrudo, J.M.; Kinson, M.S.; Todd-Brown, M.A.; Lewis, J.; Luebke, J.I. Structural and functional modifications in tau mutant mice neurons aren’t linked to the presence of NFTs. Exp. Neurol. 2010, 223, 385?93. 217. Cowan, C.M.; Bossing, T.; Page, A.; Shepherd, D.; Mudher, A. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises regular tau in vivo. Acta Neuropathol. 2010, 120, 593?04. 218. Cowan, C.M.; Mudher, A. Are tau aggregates toxic or protective in tauopathies? Front. Neurol. 2013, 13, four?14. 219.5-Ethoxypyridin-2-amine In stock Brunden, K.PMID:33502231 R.; Trojanowski, J.Q.; Lee, V.M. Proof that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 2008, 14, 393?. 220. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum. Vaccin. 2010, 6, 931?. 221. Spires-Jones, T.L.; Kopeikina, K.J.; Koffie, R.M.; de Calignon, A.; Hyman, B.T. Are tangles as toxic as they appear? J. Mol. Neurosci. 2011, 45, 438?4. 222. Patterson, K.R.; Ward, S.M.; Combs, B.; Voss, K.; Kanaan, N.M.; Morfini, G.; Brady, S.T.; Gamblin, T.C.; Binder, L.I. Heat shock protein 70 prevents each tau aggregation as well as the inhibitory effects of preexisting tau aggregates on rapidly axonal transport. Biochemistry 2011, 50, 10300?0310. 223. Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Sengupta, U.; Clos, A.L.; Jackson, G.R.; Kayed, R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-typemice. Mol. Neurodegener. 2011, 6, 39. 224. Berger, Z.; Roder, H.; Hanna, A.; Carlson, A.;.